Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03498378 | Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 | 24 | Kathryn GoldOTHER | 1 | Apr 3, 2025 |
| clinicaltrials |
| NCT04420754 | Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer | active not recruiting | Phase 1 | 70 | AffyImmune Therapeutics, Inc.INDUSTRY | 1 | Mar 30, 2025 | clinicaltrials |
| NCT03772899 | Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05034497 | Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases(ReSPECT-LM) | active not recruiting | Phase 1 | 18 | Plus TherapeuticsINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT02202772 | Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder(CGC) | active not recruiting | Phase 1 / Phase 2 | 51 | Guarionex J. DecastroOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05434312 | TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients | active not recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05917860 | Neoadjuvant ADT with TULSA in the Treatment of Intermediate Risk Prostate Cancer(NeoADT-TULSA) | active not recruiting | Phase 1 | 15 | Turku University HospitalOTHER_GOV | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04041050 | A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | active not recruiting | Phase 1 | 85 | AbbVieINDUSTRY | 14 | Feb 14, 2025 | clinicaltrials |
| NCT04881032 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma(NANO-GBM) | active not recruiting | Phase 1 / Phase 2 | 66 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT03283137 | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | active not recruiting | Phase 1 | 20 | University of ChicagoOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT05383079 | Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer(AlphaBet) | active not recruiting | Phase 1 / Phase 2 | 36 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03373097 | Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT06794957 | A Study of AL8326 in Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 158 | Advenchen Laboratories, LLCINDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03546361 | CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 24 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT04440735 | A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Kahr MedicalINDUSTRY | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05479578 | Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer | active not recruiting | Phase 1 | 7 | Rashmi Verma, MDOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT04827953 | Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer(NUMANTIA) | active not recruiting | Phase 1 / Phase 2 | 28 | Nelum CorpINDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03616886 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC(SYNERGY) | active not recruiting | Phase 1 / Phase 2 | 129 | Jules Bordet InstituteOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT05121038 | CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab(CENDIFOX) | active not recruiting | Phase 1 / Phase 2 | 50 | Anup KasiOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT04843098 | Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | active not recruiting | Phase 1 / Phase 2 | 108 | Suzhou Junde Biotechnology Co., LtdINDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03671018 | A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 422 | Hoffmann-La RocheINDUSTRY | 5 | Nov 29, 2024 | clinicaltrials |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05128487 | A Study of NDI 1150-101 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 106 | Nimbus Saturn, Inc.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03155191 | Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia(TBI-1501) | active not recruiting | Phase 1 / Phase 2 | 21 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT03153202 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | active not recruiting | Phase 1 / Phase 2 | 23 | Joshua BrodyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03845166 | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors(STELLAR-001) | active not recruiting | Phase 1 | 325 | ExelixisINDUSTRY | 10 | Nov 19, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT05199272 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | active not recruiting | Phase 1 / Phase 2 | 141 | 23andMe, Inc.INDUSTRY | 2 | Nov 15, 2024 | clinicaltrials |
| NCT04954001 | Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | active not recruiting | Phase 1 / Phase 2 | 160 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 3 | Nov 12, 2024 | clinicaltrials |
| NCT03907527 | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer | active not recruiting | Phase 1 | 71 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03927261 | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS | active not recruiting | Phase 1 | 88 | Precigen, IncINDUSTRY | 1 | Nov 8, 2024 | clinicaltrials |
| NCT05595473 | A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 with Valganciclovir (VGCV) in Subjects with Hepatocellular Carcinoma | active not recruiting | Phase 1 / Phase 2 | 42 | Rznomics, Inc.OTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2025source: clinicaltrials